Before You Schedule a Routine Colonoscopy, Read the Actual Data

For decades, Americans have been told that routine colonoscopy is the unquestioned gold standard for colorectal cancer screening. The message has often been simple: find polyps, remove them, prevent cancer, and save lives.

But informed health decisions should never be built on a slogan. They should be built on the best available evidence, the size of the potential benefit, the possible harms, and your personal risk.

The Nordic-European Initiative on Colorectal Cancer, known as the NordICC trial, was the first large randomized trial designed to measure what happens when a population is invited to undergo screening colonoscopy. Its findings were far more modest than many people expected.

That does not mean colonoscopy is useless. It does mean every person deserves the complete story before agreeing to an invasive procedure.

What the NordICC Trial Found

The original NordICC report followed 84,585 adults in Poland, Norway, and Sweden. Participants were between ages 55 and 64 when enrolled. One group received a one-time invitation to undergo screening colonoscopy, while the other group received usual care without an organized screening invitation.

Only 42 percent of those invited actually completed the colonoscopy. That detail matters because the randomized trial directly tested the real-world effect of an invitation—not the biological effect of forcing every participant to undergo the procedure.

At 10 years, colorectal cancer had been diagnosed in 0.98 percent of the invited group and 1.20 percent of the usual-care group. Colorectal cancer death occurred in 0.28 percent and 0.31 percent, respectively. Death from any cause was almost identical: 11.03 percent in the invited group and 11.04 percent in the usual-care group.

The newly published 13-year follow-up strengthens one part of the finding. Colorectal cancer incidence was 1.46 percent in the invited group compared with 1.80 percent in the usual-care group. That is a 19 percent relative reduction but an absolute difference of 0.34 percentage points.

Colorectal cancer mortality at 13 years was 0.41 percent in the invited group and 0.47 percent in the usual-care group. The difference was not statistically significant. The investigators concluded that one invitation to colonoscopy significantly reduced colorectal cancer incidence but did not significantly reduce colorectal cancer mortality over 13 years.

That is the honest headline: fewer colorectal cancer diagnoses, but no proven mortality reduction in the randomized intention-to-screen comparison at 13 years.

Why the Trial Does Not Prove That Colonoscopy “Does Nothing”

The trial has to be interpreted carefully. Because fewer than half of the invited participants underwent colonoscopy, the results likely dilute any benefit received by people who actually completed the procedure.

The researchers also published per-protocol estimates suggesting larger reductions among people who underwent colonoscopy. However, per-protocol comparisons lose some of the protection created by randomization. People who choose screening may differ from people who decline it in ways that also affect their health. Those estimates are useful, but they are not as definitive as the randomized intention-to-screen results.

Thirteen years may still be too short to reveal the full mortality effect of removing slow-growing precancerous lesions. Colonoscopy quality also depends heavily on the skill of the endoscopist, bowel preparation quality, complete visualization of the colon, and the adenoma detection rate.

The responsible conclusion is not “everyone needs a colonoscopy” or “no one needs a colonoscopy.” The responsible conclusion is that the benefit is more nuanced than the public has often been told.

Colonoscopy Has Real Risks

Colonoscopy is generally considered safe, but it is not risk-free. Potential harms include major bleeding, bowel perforation, infection, complications from sedation or anesthesia, fluid and electrolyte disturbances from bowel preparation, and follow-up procedures triggered by uncertain findings.

In the original NordICC trial, 15 people experienced major bleeding after polyp removal. No screening-related deaths occurred within 30 days, and the trial reported no perforations. Outside this trial, large reviews confirm that bleeding and perforation are uncommon but real, with risk increasing after polyp removal and generally rising with age.

Research also shows that bowel cleansing can cause measurable short-term changes in gut microbial composition and metabolites. Many people appear to move back toward their baseline microbiome after the procedure, but recovery varies, and the long-term clinical importance of these changes is not fully understood. This is not proof that bowel preparation causes heart disease. It is another reason to respect the gut and avoid pretending that an invasive procedure is biologically neutral.

My Only Recommendation for Routine Screening: Cologuard

At Natural Heart Doctor, my only recommendation for routine colorectal cancer screening is the Cologuard stool DNA test for appropriate average-risk adults.

The newer Cologuard Plus test is an FDA-approved, prescription-based test for adults age 45 and older who are at average risk for colorectal cancer. It is completed at home and analyzes a stool sample for colorectal neoplasia-associated DNA markers and hidden blood. There is no bowel preparation, sedation, anesthesia, recovery time, or instrument placed inside the colon.

A Cologuard test is generally repeated every three years for an eligible average-risk adult. It is not perfect. False-positive and false-negative results can occur. A negative result does not guarantee that cancer or an advanced precancerous lesion is absent. A positive result does not prove cancer, but the FDA labeling states that it should be followed by diagnostic colonoscopy.

Cologuard is not intended for people with symptoms or those at increased risk, including certain people with a personal history of colorectal cancer or advanced precancerous lesions, inflammatory bowel disease, hereditary cancer syndromes, or other significant risk factors. Rectal bleeding, black stool, iron-deficiency anemia, unexplained weight loss, or a persistent change in bowel habits requires medical evaluation—not routine screening.

The distinction matters. My recommendation for routine screening is Cologuard. Diagnostic evaluation for symptoms, a positive Cologuard result, or a high-risk history is a separate medical decision.

Gut Health Leads to Heart Health

The conversation should not end with cancer screening. Your intestinal tract is connected to your immune system, metabolism, blood vessels, brain, and heart.

At Natural Heart Doctor, our root-cause framework is simple: too much bad stuff and not enough good stuff can disrupt the gut microbiome and weaken the intestinal barrier. That may allow bacterial products such as lipopolysaccharide, or LPS, to interact more intensely with the immune system. This is the same pattern I describe in Forget Cholesterol Alone: Your Gut May Be the Hidden Driver of Heart Disease.

The downstream pattern can include immune activation, chronic inflammation, oxidative stress, and endothelial dysfunction. The endothelium is the delicate inner lining of your blood vessels. When that lining is injured, blood pressure, insulin sensitivity, vascular function, clotting balance, and cardiovascular risk can all move in the wrong direction.

Gut microbes also produce short-chain fatty acids and other metabolites that interact with vascular tone, immune signaling, glucose regulation, and the integrity of the gut barrier. This is why gut health is not merely about gas, bloating, constipation, or diarrhea. Gut health is heart health. It is also why so many seemingly unrelated complaints, including menopausal symptoms, trace back to the same terrain.

The root-cause plan is not to chase one symptom or one lab number. It is to Eat Well, Live Well, Think Well, and Test, Don’t Guess.

Test, Don’t Guess With the Gut Zoomer

If you want real information about your gut health, consider the Gut Zoomer from Natural Heart Doctor.

The Gut Zoomer is an advanced at-home assessment that uses stool and timed urine samples to evaluate 14 categories and more than 200 markers. It examines beneficial and potentially disruptive gut microbes, bacteria, viruses, parasites, fungi, microbial diversity, intestinal inflammation, digestive and immune balance, permeability-related markers, malabsorption, bile acids, short-chain fatty acids, beta-glucuronidase, antibiotic-resistance genes, and gut-brain neurochemistry.

Markers include calprotectin, lactoferrin, zonulin, secretory IgA, pancreatic elastase, anti-LPS antibodies, fecal fat, stool pH, and multiple microbial metabolites. The panel can help connect patterns involving digestion, immune activation, intestinal barrier integrity, and inflammation to a more personalized root-cause plan.

The collection is completed at home, the prepaid kit is returned to the laboratory, and health-professional interpretation is included with the purchase. Results are generally expected in about 14 days after the laboratory receives the samples.

The Gut Zoomer is not a colorectal cancer screening test and does not replace Cologuard or the evaluation of concerning symptoms. It answers a different question: What is happening inside the gut environment that may be contributing to inflammation, poor digestion, altered barrier function, or broader health problems?

Order the Gut Zoomer and stop guessing about your gut health.

The Natural Heart Doctor Bottom Line

TEST, DON’T GUESS. Order the Gut Zoomer from Natural Heart Doctor.

The largest randomized colonoscopy trial found a modest absolute reduction in colorectal cancer diagnoses but no statistically significant reduction in colorectal cancer death after 13 years in the group invited to screening. That finding deserves to be discussed honestly.

For an eligible, average-risk adult without symptoms, my only routine colorectal cancer screening recommendation is Cologuard. A positive Cologuard result, concerning symptoms, previous advanced lesions, inflammatory bowel disease, a hereditary cancer syndrome, or another high-risk feature is no longer a routine screening situation and requires individualized diagnostic evaluation.

At the same time, do not confuse cancer screening with building health. Screening looks for evidence of disease. Root-cause care asks why the terrain became vulnerable in the first place.

Protect the gut. Support the intestinal barrier. Reduce toxic exposures. Eat nutrient-dense real food. Get outside, move, sleep, manage stress, and build community. Then test what matters instead of guessing. Want help building that plan? Schedule a free heart health discovery call.

Because gut health leads to heart health—and your heart is listening to everything happening in your gut.

References

• Kaminski MF, Kalager M, Løberg M, et al. Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: update from the NordICC randomised trial. The Lancet. 2026.
• Bretthauer M, Løberg M, Wieszczy P, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. New England Journal of Medicine. 2022;387:1547–1556.
• U.S. Food and Drug Administration. Cologuard Plus Premarket Approval. FDA-approved indication and labeling.
• American Cancer Society. Colorectal Cancer Screening Tests. Cologuard and Cologuard Plus screening interval.
• Kindt IS, et al. The risk of bleeding and perforation from sigmoidoscopy or colonoscopy in colorectal cancer screening: a systematic review and meta-analysis. 2023.
• Nagata N, et al. Effects of bowel preparation on the human gut microbiome and metabolome. Scientific Reports. 2019.
• Di Vincenzo F, et al. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Internal and Emergency Medicine. 2024.
• Nesci A, et al. Gut Microbiota and Cardiovascular Disease. 2023.

Medical disclaimer: This article is for educational purposes only and is not medical advice. Do not delay or avoid evaluation for rectal bleeding, black stool, iron-deficiency anemia, unexplained weight loss, persistent changes in bowel habits, severe abdominal symptoms, or other concerning findings. Discuss colorectal cancer screening and any diagnostic testing with a qualified healthcare professional who knows your history.

Dr. Jack Wolfson DO
Cardiologist and Founder of Natural Heart Doctor